JP MORGAN/PUT/VERTEX PHARMACEUTICALS/305/0.1/21.06.24 | Market Closed - Börse Stuttgart 09:34:32 31/05/2024 BST | ||
| 0.001 EUR | -.--% |
|
| 3 months | -99.29% | ||
| 6 months | -99.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
Static data
| Product type | Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL1GKQ |
| ISIN | DE000JL1GKQ5 |
| Date issued | 23/03/2023 |
| Strike | 305 $ |
| Maturity | 21/06/2024 (13 Days) |
| Parity | 10 : 1 |
| Emission price | 3.29 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.88 € |
|---|---|
| Lowest since issue | 0.001 € |
| Delta | -0.04x |
| Omega | 9.952 |
| Premium | 32.43x |
| Gearing | 274.25x |
| Moneyness | 0.6794 |
| Difference Strike | -178 $ |
| Difference Strike % | -58.37% |
| Spread | 0.299 € |
| Spread % | 99.67% |
| Theoretical value | 0.1505 |
| Implied Volatility | 96.73 % |
| Total Loss Probability | 94.11 % |
| Intrinsic value | 0.000000 |
| Present value | 0.1505 |
| Break even | 303.36 € |
| Theta | -0.1x |
| Vega | 0.01x |
| Rho | -0x |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant